Availability of Safe and Effective Therapeutic Options to Pregnant and Lactating Individuals Following the United States Food and Drug Administration Pregnancy and Lactation Labeling Rule - 22/08/23
, Maryann Mazer-Amirshahi, PharmD, MD, MPH 3, Elimika Pfuma Fletcher, PharmD, PhD 4, Gerhard Fusch, PhD 2, Olsen Chan, BHSc 2, Arya Aghayi, BSc 5, Anthony K.C. Chan, MD 6, Thierry Lacaze-Masmonteil, MD, PhD 7, Johannes Van Den Anker, MD, PhD 8, 9, Samira Samiee-Zafarghandy, MD 10Abstract |
Objective |
To explore the extent and type of pregnancy and lactation data of newly approved prescription drugs and assess whether the presented recommendations are data-driven, as required by the US Food and Drug Administration Pregnancy and Lactation Labeling Rule implemented in 2015.
Study design |
In this descriptive analysis, we reviewed pregnancy and lactation data of all new molecular entities approved between 2001 and 2020 in their most updated labeling. Information was collected regarding the pregnancy and lactation risk statements, the source of pregnancy and lactation data, and the design and methods of pregnancy and lactation studies in the labeling.
Results |
Of the 422 new molecular entities, the key advisory statement for use of 133 (32%) drugs in pregnancy and 194 (46%) drugs in lactation were classified as “against use.” Less than 2% of all drugs had a key advisory statement that supported their use during pregnancy or lactation. The sources of data regarding use in pregnancy were studies in human and animals in 46 (11%) and 348 (82%) drugs, respectively. For use during lactation, data included studies in human and animals in 23 (5%) and 251 (59%) drugs, respectively. The key advisory recommendation was consistent with the available human information in 4 (8%) drugs in pregnancy and 3 (13%) drugs in lactation. Prescription drug labeling contains limited data to support informed decision-making for the use of prescription drugs during pregnancy/lactation. Close collaboration among stakeholders is required to enhance the availability of data in this population.
Le texte complet de cet article est disponible en PDF.Abbreviations : AED, FDA, NME, PLLR
Plan
| This article reflects the views of the author and should not be construed to represent Food and Drug Administration views or policies. The authors report no conflict of interest. |
Vol 259
Article 113342- août 2023 Retour au numéro
Article précédent
- Adolescent Decision-Making Involvement in the Receipt of Genomic Testing Results
- Anne E. Berset, Melanie F. Myers, Cynthia A. Prows, William B. Brinkman
- Racial Disparities in Mental Health Disorders in Youth with Chronic Medical Conditions
- Vincent J. Gonzalez, Rachel T. Kimbro, John C. Shabosky, Stefan Kostelyna, Titilope Fasipe, Natalie Villafranco, Katherine E. Cutitta, Keila N. Lopez
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?